Everyday Health vs Flo

Everyday Health Survey Finds Widespread GLP-1 Satisfaction, New Opportunities for Long-Term Success

Everyday Health has published findings from its survey on patient experiences with GLP-1 medications among individuals with obesity and type 2 diabetes. While over 80 percent of users report satisfaction and improved health metrics, significant gaps exist regarding long-term side effect guidance and provider communication. Everyday Health announced it is developing consumer resources to support patient education, healthcare providers, and health influencers across the GLP-1 journey.

• Ninety percent of U.S. adults are aware of GLP-1 medications for weight loss, and 15 percent report having used them.
• Eighty-two percent of current GLP-1 users with obesity report satisfaction with their treatment, and 88 percent with type 2 diabetes report improved blood sugar/A1C.
• Only 12 percent of patients with obesity who discontinued GLP-1 treatment recall their provider explaining what happens after stopping.

Buzzy GLP-1 Drug Retatrutide Led to Dramatic Weight Loss in Diabetes Trial

Everyday Health published an article on September 29, 2026 reporting that retatrutide, a GLP-1 drug, led to dramatic weight loss in a diabetes trial. The full article text was inaccessible due to a JavaScript-disabled error, so specific trial data could not be verified. The headline indicates significant weight loss outcomes associated with the drug.

• Everyday Health published an article on September 29, 2026 with the headline: 'Buzzy GLP-1 Drug Retatrutide Led to Dramatic Weight Loss in Diabetes Trial'.
• The article reports that retatrutide, a GLP-1 drug, led to dramatic weight loss in a diabetes trial.
• The full article text was not accessible due to a JavaScript-disabled error, so additional specific trial figures are unavailable.

Everyday Health Releases Metabolic Health Benchmark Report: National Consumer Understanding

Everyday Health announced the release of its Metabolic Health Benchmark Report, which focuses on national consumer understanding of metabolic health. The announcement was published on August 18, 2026, on the Everyday Health website.

• Everyday Health released a Metabolic Health Benchmark Report on August 18, 2026.
• The report addresses national consumer understanding of metabolic health.
• The announcement was published on Everyday Health's official website.

Vienna Startup Ovulyx Launches Couples-Focused Cycle Tracking App

Stefan Renzler, a Vienna-based developer, has launched Ovulyx, a cycle tracking app designed for couples, allowing both partners to view cycle phases and share an experience log to discover what helps during each phase. Users can track mood, energy, symptoms, and bleeding, with predictions for period, PMS, and fertile window. Partners connect via an invitation code and see a dedicated view with supportive actions. The app also supports trying for a baby and menopause, and allows import from Flo and MyNFP. Available on iOS, Android, and web in 29 languages across 152 countries, it offers a 30-day free trial, with Premium at €4.99 monthly or €49.99 yearly. Prioritizing privacy, data is stored in Western Europe under GDPR, and the app does not sell data or use health data for advertising. Ovulyx competes with Flo for Partners and Clue Connect.

• Ovulyx is a cycle tracking app for couples, launched by Vienna-based developer Stefan Renzler.
• The app is available on iOS, Android, and web in 29 languages across 152 countries.
• Premium costs €4.99 per month or €49.99 per year after a 30-day free trial, including one partner connection.

CIPA Private Right of Action Kept, Shifting Privacy to Research

California's legislature passed a compromise version of SB-690, maintaining most of the private right of action provisions of the California Invasion of Privacy Act (CIPA). This means that juries, rather than regulators, will set privacy standards in the state, as individuals can sue companies for online tracking practices. With over 4,000 CIPA lawsuits filed, mostly against legitimate businesses, the shift emphasizes the need for companies to align data practices with consumer (and juror) expectations. The author argues that privacy compliance should now be research-driven, focusing on customer attitudes, rather than purely legal compliance. This could lead to a competitive advantage for customer-centric businesses over Big Tech, which may face greater legal exposure.

• California passed a compromise version of SB-690, preserving most of the private right of action under CIPA.
• More than 4,000 CIPA lawsuits have been filed, mostly against legitimate businesses.
• A jury verdict against Meta involved data collection from the Flo menstrual tracking app.

Flo Health Appoints Rina Hahn as Chief Marketing Officer

Flo Health has appointed Rina Hahn as Chief Marketing Officer, announced August 26, 2026.